Anthrax

Emergent BioSolutions, Inc., releases update on BioThrax procurement contract with CDC

Emergent BioSolutions, Inc., released an update on Friday of the status of its 2011 procurement contract for BioThrax with the…

8 years ago

HHS, Emergent BioSolutions enter into contract for anthrax vaccine development

The U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) recently…

8 years ago

Emergent BioSolutions, Inc., signs multi-year contract for next-gen anthrax vaccine candidate

Emergent BioSolutions, Inc., announced on Friday that it has signed a multi-year contract for the advanced development and delivery of…

8 years ago

Elusys Therapeutics publishes clinical trial data supporting approval for anthrax treatment

Elusys Therapeutics, Inc., published data on Thursday on more than 450 healthy adult subjects from five clinical trials used to…

8 years ago

FDA approves sBLA for Biothrax manufacture at Emergent BioSolutions’ Building 55

The U.S. Food and Drug Administration (FDA) recently approved Emergent BioSolutions, Inc.’s supplemental Biologics License Application (sBLA) for the manufacture…

8 years ago

Altimmune, BARDA set for clinical trial of single-dose anthrax vaccine

Altimmune, Inc., and the Biomedical Advanced Research and Development Authority (BARDA) are set to advance the first clinical trial later…

8 years ago

NIH: Engineered anthrax toxins could help treat cancerous tumors

Scientists at the National Institutes of Health (NIH) on Monday described how combining engineered anthrax toxin proteins and existing chemotherapy…

8 years ago

HHS solicitations signal intent to maintain SNS anthrax vaccine stockpile

The U.S. Department of Health and Human Services (HHS) issued two solicitation notices on Tuesday related to the development and…

8 years ago

FDA completes Pre-Approval Inspection of Emergent BioSolutions’ Building 55 BioThrax manufacturing facility

The U.S. Food and Drug Administration (FDA) completed its Pre-Approval Inspection (PAI) of Emergent BioSolutions, Inc.’s Building 55 for the…

8 years ago

FDA accepts for review Emergent BioSolutions’ sBLA for Building 55 Biothrax production

Emergent BioSolutions, Inc.’s supplemental Biologics License Application (sBLA) seeking approval for the manufacture of BioThrax (anthrax vaccine adsorbed) at the…

8 years ago

FDA grants orphan drug status to Emergent BioSolutions, Inc.’s BioThrax

The U.S. Food and Drug Administration (FDA) granted orphan drug status to Emergent BioSolutions, Inc., on Wednesday for BioThrax (anthrax…

8 years ago

Energy and Commerce subcommittee examines U.S. biological threat preparedness

The Energy and Commerce Committee Subcommittee on Health held a hearing entitled “Examining H.R. 3299, Strengthening Public Health Response Act”…

8 years ago

HHS supporting the development of single dose nasal spray anthrax vaccine

The U.S. Department of Health and Human Services (HHS) announced on Monday that one of the nation’s Centers for Innovation…

8 years ago

Emergent BioSolutions submits sBLA to the FDA for increased BioThrax manufacturing capabilities

Emergent BioSolutions, Inc., submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) on Monday…

8 years ago

FDA approves new anthrax treatment

The U.S. Food and Drug Administration (FDA) on Friday approved the Anthim injection to treat inhalation anthrax in combination with…

8 years ago

This website uses cookies.